TYRA (Tyra Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TYRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-01 | ROBERT J MORE | Director | A | — | — |
| 2026-06-01 | Adele M. Gulfo | Director | A | — | — |
| 2026-06-01 | Rehan Verjee | Director | A | — | — |
| 2026-06-01 | Stephen Michael Rothenberg | Director | A | — | — |
| 2026-06-01 | Jake Simson | Director | A | — | — |
| 2026-06-01 | Susan Moran | Director | A | — | — |
| 2026-06-01 | RA Capital Nexus Fund, L.P. | Director | A | — | — |
| 2026-05-07 | Alan Fuhrman | Chief Financial Officer | A | — | — |
| 2026-05-07 | Bhavesh Ashar | Chief Operating Officer | A | — | — |
| 2026-05-07 | Yuliya Rueb | Vice President, Finance (PAO) | A | — | — |
| 2026-05-07 | Todd Harris | President and CEO | A | — | — |
| 2026-05-07 | Douglas J Warner | Chief Medical Officer | A | — | — |
| 2026-04-20 | Habib J Dable | Director | A | — | — |
| 2026-03-27 | GILLA KAPLAN | Director | MIXED | — | — |
| 2026-03-17 | Alan Fuhrman | Chief Financial Officer | A | — | — |
| 2026-03-17 | Todd Harris | President and CEO | A | — | — |
| 2026-02-13 | Daniel Bensen | Chief Discovery Officer | Sell | — | — |
| 2026-01-20 | Daniel Bensen | Chief Discovery Officer | Sell | — | — |
| 2025-12-19 | ROBERT J MORE | Director | Sell | — | — |
| 2025-12-16 | Daniel Bensen | Chief Discovery Officer | Sell | — | — |
| 2025-12-01 | Bhavesh Ashar | Chief Operating Officer | A | — | — |
| 2025-11-25 | ROBERT J MORE | Director | Sell | — | — |
| 2025-11-19 | Daniel Bensen | Chief Operating Officer | Sell | — | — |
| 2025-11-17 | Daniel Bensen | Chief Operating Officer | Sell | — | — |
| 2025-09-17 | Alan Fuhrman | Chief Financial Officer | A | — | — |
| 2025-08-07 | Douglas J Warner | Chief Medical Officer | A | — | — |
| 2025-08-07 | Daniel Bensen | Chief Operating Officer | A | — | — |
| 2025-08-07 | Todd Harris | President and CEO | A | — | — |
| 2025-08-07 | Alan Fuhrman | Chief Financial Officer | A | — | — |
| 2025-06-20 | GILLA KAPLAN | Director | Sell | — | — |
| 2025-06-16 | GILLA KAPLAN | Director | Sell | — | — |
| 2025-06-16 | Rajeev M. Shah | Director | Buy | — | — |
| 2025-06-11 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | — | — |
| 2025-06-06 | RA Capital Healthcare Fund LP | Director | Buy | — | — |
| 2025-06-02 | Susan Moran | Director | A | — | — |
| 2025-06-02 | Jake Simson | Director | A | — | — |
| 2025-06-02 | ROBERT J MORE | Director | A | — | — |
| 2025-06-02 | Stephen Michael Rothenberg | Director | A | — | — |
| 2025-06-02 | Rehan Verjee | Director | A | — | — |
| 2025-06-02 | GILLA KAPLAN | Director | A | — | — |
| 2025-06-02 | RA Capital Healthcare Fund LP | Director | A | — | — |
| 2025-03-18 | Todd Harris | President and CEO | A | — | — |
| 2025-03-18 | Alan Fuhrman | Chief Financial Officer | A | — | — |
| 2025-02-07 | Nina S Kjellson | Director | Sell | — | — |
| 2025-01-31 | Adele M. Gulfo | Director | A | — | — |
| 2025-01-27 | Nina S Kjellson | Director | Sell | — | — |
| 2025-01-21 | Nina S Kjellson | Director | Sell | — | — |
| 2024-11-26 | Nina S Kjellson | Director | Sell | — | — |
| 2024-11-13 | RA Capital Healthcare Fund LP | Director | Buy | — | — |
| 2024-11-08 | Nina S Kjellson | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 10,127,311 | — |
| — | Director | 9,695,820 | — |
| — | Director | 8,477,275 | — |
| — | 10%+ Owner | 6,534,298 | — |
| — | 10%+ Owner | 6,448,359 | — |
| — | — | 4,448,359 | — |
| — | 10%+ Owner | 3,936,595 | — |
| — | 10%+ Owner | 3,924,046 | — |
| — | Director | 3,823,425 | — |
| — | President and CEO | 1,437,631 | — |
| — | — | 757,432 | — |
| — | Director | 443,885 | — |
| — | Director | 442,721 | — |
| — | Chief Technology Officer | 273,576 | — |
| — | Chief Scientific Officer | 273,254 | — |
| — | Chief Financial Officer | 240,542 | — |
| — | Director | 192,783 | — |
| — | Chief Discovery Officer | 152,853 | — |
| — | Chief Medical Officer | 86,435 | — |
| — | Chief Development Officer | 73,794 | — |
| — | Vice President, Finance (PAO) | 43,354 | — |
| — | Director | 42,526 | — |
| — | Chief Financial Officer | 36,164 | — |
| — | Chief Medical Officer | 25,000 | — |
| — | Chief Operating Officer | 15,013 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TYRA quote page; the site-wide leaderboard is on the insider transactions hub.